AssetMark’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
Other funds holding PTGX
AssetMark's PTGX Position: Q3 2026 in Review
AssetMark increased its Protagonist Therapeutics (PTGX) stake by 1.3% in Q3 2026, buying an estimated $179K and bringing the position to 99,941 shares worth $14.1M. The position accounts for 0.02% of the portfolio, ranked #485.
AssetMark first reported a position in PTGX in Q4 2017 and has held it in 10 quarters since. 294 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.
- AssetMark held 99,941 shares of Protagonist Therapeutics worth $14.1M as of Q3 2026.
- AssetMark bought 1,254 Protagonist Therapeutics shares in Q3 2026, an estimated $179K.
- Protagonist Therapeutics made up 0.02% of AssetMark's portfolio in Q3 2026, its #485 holding.
- AssetMark first reported a position in Protagonist Therapeutics in Q4 2017 and has held it in 10 quarters since.
- 294 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.